PMID- 26550444
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151109
LR  - 20220408
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 8
DP  - 2015
TI  - Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer 
      cells in the treatment of non-small-cell lung cancer.
PG  - 14527-37
AB  - BACKGROUND: Non-small-cell lung cancer (NSCLC) is one of the most fatal cancers, 
      which leads to large number of people dead. Followed by surgery, chemotherapy and 
      radiotherapy, chemotherapy combined dendritic cells with cytokine-induced killer 
      cells (DC-CIK) immunotherapy has been applied in NSCLC for some time, but little 
      consistent beneficial results are provided. So, it is essential to weigh the pros 
      and cons of the new therapeutic method. METHODS: We searched the randomized 
      controlled trials of NSCLC mainly by PubMed database. Terms combination of 
      "cytokine-induced killer cells", "tumor" and "cancer" were used. After evaluating 
      the heterogeneity of selected studies, then we performed the meta-analysis. 
      Pooled risk ratios (RRs) were estimated and 95% confidence intervals (CIs) were 
      calculated using a fixed-effect model. Sensitivity analysis was also performed. 
      RESULTS: Six eligible trials were enrolled. Efficiency and safety of chemotherapy 
      followed by DC-CIK immunotherapy (experimental group) and chemotherapy alone 
      (control group) were compared. 1-year overall survival (OS) (P=0.02) and 
      progression free survival (PFS) (P=0.005) in the experimental group were 
      significantly increased compared with the control. Disease control rate (DCR) 
      (P=0.006) rose significantly in experimental group. However, no significant 
      differences between the two groups were observed in 2-year OS (P=0.21), 2-year 
      PFS (P=0.10), overall response rate (ORR) (P=0.76) and partial response (PR) 
      (P=0.22). Temporary fever, anemia, leukopenia and nausea were the four major 
      adverse events (AEs) treated by chemotherapy. The incidence of anemia, leukopenia 
      and nausea in the experimental group was obviously lower than the control group. 
      Temporary fever rate was higher in experimental group than that in the control, 
      but could be alleviated by taking sufficient rest. CONCLUSIONS: Chemotherapy 
      combined with DC-CIK immunotherapy showed superiority in DCR, 1-year OS and PFS, 
      and no more AEs appeared, however, there was no significant improvement in ORR, 
      PR, 2-year OS and PFS. As a whole, the combination therapy is safer but modest in 
      efficacy for advanced NSCLC patients.
FAU - Zheng, Chenhong
AU  - Zheng C
AD  - Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital 
      Beijing 100853, China ; Department of Chinese PLA General Logistics, No. 2 
      Clinic, Management Support Bureau Beijing 100071, China.
FAU - Yu, Ganjun
AU  - Yu G
AD  - Institute of Immunology, National Key Laboratory of MedicalImmunology & Second 
      Military Medical University 800 Xiangyin Road, Shanghai 200433, China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Plastic Surgery, Shanghai Changzheng Hospital, Second Military 
      Medical University Shanghai, China.
FAU - Tang, Airong
AU  - Tang A
AD  - Department of General Medicine, Beijing Tieying Hospital Beijing 100079, China.
FAU - Geng, Peiliang
AU  - Geng P
AD  - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support 
      Bureau Beijing 100071, China.
FAU - Zhang, Huiming
AU  - Zhang H
AD  - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support 
      Bureau Beijing 100071, China.
FAU - Zhu, Zhiquan
AU  - Zhu Z
AD  - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support 
      Bureau Beijing 100071, China.
FAU - Li, Fang
AU  - Li F
AD  - Department of Chinese PLA General Logistics, No. 2 Clinic, Management Support 
      Bureau Beijing 100071, China.
FAU - Xie, Xiaohua
AU  - Xie X
AD  - Department of Comprehensive Surgery, South Building, Chinese PLA General Hospital 
      Beijing 100853, China.
LA  - eng
PT  - Journal Article
DEP - 20150815
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4613129
OTO - NOTNLM
OT  - DC-CIK
OT  - Dendritic cells
OT  - NSCLC
OT  - chemotherapy
OT  - cytokine-induced killer cells
OT  - immunotherapy
EDAT- 2015/11/10 06:00
MHDA- 2015/11/10 06:01
PMCR- 2015/08/15
CRDT- 2015/11/10 06:00
PHST- 2015/04/26 00:00 [received]
PHST- 2015/07/10 00:00 [accepted]
PHST- 2015/11/10 06:00 [entrez]
PHST- 2015/11/10 06:00 [pubmed]
PHST- 2015/11/10 06:01 [medline]
PHST- 2015/08/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Aug 15;8(8):14527-37. eCollection 2015.